SecBot SecBot
PRESS-RELEASE ·Filed May 8, 2026

BIIB

Biogen Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▼ Bearish

The 3-month PDUFA delay removes a near-term catalyst and introduces execution risk. Monitor for any further FDA requests or competitor developments. The stock may trade lower on the delay, but the lack of approvability concerns limits downside. Watch for updates on the August 24, 2026 PDUFA date.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$192.75
T+0 close · May 8, 2026 · via day close
Latest settled
+4.71%
T+60 · $201.82
Vs SPY
+1.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $192.75entry
  2. T+1 · 6mo ago +2.38%α +2.14% · $197.33
  3. T+5 · 6mo ago −0.71%α −2.18% · $191.37
  4. T+20 · 5mo ago +1.35%α +1.32% · $195.34
  5. T+60 · 3mo ago +4.71%α +1.99% · $201.82

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Biogen and Eisai announced a 3-month FDA review extension for the sBLA of LEQEMBI IQLIK (once-weekly subcutaneous injection) as a starting dose for early Alzheimer's disease, pushing the PDUFA date to August 24, 2026. The FDA requested additional information, classifying it as a major amendment, but has not raised approvability concerns. This delay introduces uncertainty around the launch timeline for the subcutaneous formulation, which is key to expanding patient access and convenience.

Key Facts

  • FDA extended review period by 3 months for LEQEMBI IQLIK subcutaneous starting dose sBLA
  • New PDUFA action date is August 24, 2026 (previously May 2026)
  • FDA classified the additional information request as a major amendment
  • FDA has not raised any concerns regarding approvability to date
  • Subcutaneous maintenance dosing was already approved on August 26, 2025
  • LEQEMBI is approved in over 50 countries worldwide

Financial Impact

Delay of up to 3 months in potential approval of subcutaneous starting dose, which could affect adoption ramp and revenue trajectory for LEQEMBI IQLIK. No specific financial figures provided.

revenueproduct adoption timeline

Risk Factors

  • Further FDA requests could extend review beyond August 2026
  • Competing Alzheimer's treatments may gain market share during delay
  • Adoption of subcutaneous formulation may be slower if approval is further delayed

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
56% bullish (43 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3290827

Track record

34 reports on BIIB

Performance horizon

10 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 15 of 16 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
  4. Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  6. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
  7. Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
  8. Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
  9. Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
  10. Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (11h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026